Holen Sie sich die Stockscreener-App
1.53
3.77%
-0.06
Handel nachbörslich:
1.60
0.07
+4.58%
Schlusskurs vom Vortag:
$1.59
Offen:
$1.6
24-Stunden-Volumen:
425.58K
Relative Volume:
0.75
Marktkapitalisierung:
$189.38M
Einnahmen:
$7.05M
Nettoeinkommen (Verlust:
$-30.43M
KGV:
-4.0391
EPS:
-0.3788
Netto-Cashflow:
$21.84M
1W Leistung:
-1.92%
1M Leistung:
+36.61%
6M Leistung:
-61.36%
1J Leistung:
-22.73%
1-Tages-Spanne:
$1.52
$1.61
1-Wochen-Bereich:
$1.47
$1.70
52-Wochen-Spanne:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PRQR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.53 | 189.38M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-29 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Herabstufung | Stifel | Buy → Hold |
| 2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
| 2021-05-03 | Eingeleitet | Stifel | Buy |
| 2021-03-25 | Bestätigt | Citigroup | Buy |
| 2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-15 | Eingeleitet | Citigroup | Buy |
| 2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
| 2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
| 2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | - GuruFocus
Oppenheimer Adjusts ProQR Therapeutics N.V Price Target to $9 From $15, Maintains Outperform Rating - marketscreener.com
ProQR (PRQR) Price Target Cut by Oppenheimer Amid Clinical Updates | PRQR Stock News - GuruFocus
DAFNA Capital Management LLC Has $4.15 Million Stake in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences - GlobeNewswire
Raymond James Financial Inc. Invests $260,000 in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of “Buy” from Analysts - Defense World
ProQR: Q1 Earnings Snapshot - News-Times
1,181,413 Shares in ProQR Therapeutics (NASDAQ:PRQR) Acquired by ArrowMark Colorado Holdings LLC - MarketBeat
New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR) - simplywall.st
ProQR Therapeutics NV earnings missed, revenue topped estimates By Investing.com - Investing.com Nigeria
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ProQR Therapeutics NV earnings missed, revenue topped estimates - Investing.com
ProQR (PRQR) Reports Q1 Revenue Growth and Strategic Milestones - GuruFocus
ProQR Reports Q1 2025 Financial Results Amid Rising R&D Costs - TipRanks
ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial Position - Nasdaq
ProQR Announces First Quarter 2025 Operating and Financial Results - GlobeNewswire
ProQR Therapeutics (PRQR) Expected to Announce Earnings on Thursday - MarketBeat
Invesco Ltd. Purchases Shares of 11,887 ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Issue Forecasts for PRQR FY2025 Earnings - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Acquired by Boothbay Fund Management LLC - MarketBeat
ProQR Therapeutics N.V (NASDAQ: PRQR) Posted 2.58% Gain This Year: What’s Next? - Stocksregister
JPMorgan Chase & Co. Has $142,000 Holdings in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Evercore ISI Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
ProQR Therapeutics NV expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ProQR Announces Webcast of Presentation at the 2025 Citizens Lif - GuruFocus
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference | PRQR Stock News - GuruFocus
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference - GlobeNewswire
RNA Editing Pioneer ProQR to Showcase Breakthrough Axiomer Platform at Major Healthcare Conference - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Earns Outperform Rating from Analysts at Evercore ISI - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Research Coverage Started at Cantor Fitzgerald - Defense World
Adage Capital Partners GP L.L.C. Purchases 5,976,813 Shares of ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 - The Manila Times
ProQR Therapeutics N.V [PRQR] Investment Appeal on the Rise - knoxdaily.com
RNA Editing Market Deep Research 2025-2032 | QIAGEN N.V., ProQR - openPR.com
Evercore ISI Group Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Outperform Recommendation - Nasdaq
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald - Yahoo Finance
ProQR Therapeutics initiated with an Outperform at Evercore ISI - Yahoo Finance
XTX Topco Ltd Takes $163,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - The AM Reporter
Riding the Waves: A Guide to Investing in PRQR Stock - investchronicle.com
Evercore ISI sets ProQR stock Outperform with $5 target By Investing.com - Investing.com India
ProQR Therapeutics (PRQR) Receives Overweight Rating and $8 Pric - GuruFocus
Cantor Fitzgerald sets $8 price target on ProQR shares with Overweight rating - Investing.com
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):